Renal impairment has no clinically relevant effect on the long-term exposure of linagliptin in patients with type 2 diabetes

American Journal of Therapeutics

Volumn 20, Issue 6, 2013, Pages 618-621

  Friedrich, Christian ^a   Emser, Angela ^a   Woerle, Hans Juergen ^a   Graefe Mody, Ulrike ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Linagliptin; Renal impairment; Type 2 diabetes

Indexed keywords

INSULIN; LINAGLIPTIN; PLACEBO; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GEOMETRY; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN TREATMENT; KIDNEY FUNCTION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOKINETIC PARAMETERS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEVERE RENAL IMPAIRMENT; TREATMENT DURATION; KIDNEY FAILURE; META ANALYSIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX;

AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 84904379996     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31826232dc     Document Type: Article

References (17)

1. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S12-S154.
2. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608-2617.
3. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123:133-143.
4. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed November 9, 2011.
5. Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86:444-456.
6. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010;38:667-678.
7. Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010;12:648-658.
8. Baetta R, Corsini A. Pharmacology of dipeptidyl pepti-dase-4 inhibitors: similarities and differences. Drugs. 2011;71:1441-1467.
9. Novartis Pharmaceuticals UK Ltd. Summary of product characteristics: Galvus 50 mg tablets. Available at: http://www.medicines.org.uk/EMC/medicine/20734/SPC/Galvus%2050%20mg%20Tablets/. Accessed April 9, 2012.
10. Merck & Co. Inc. Highlights of prescribing information: Januvia (sitagliptin) tablets. Available at: http://www. merck.com/product/usa/pi-circulars/j/januvia/januvia-pi. pdf. Accessed April 9, 2012.
11. Bristol-Myers Squibb. Highlights of prescribing information: Onglyza (saxagliptin) tablets. Available at: http://packageinserts.bms.com/pi/pi-onglyza.pdf. Accessed April 9, 2012.
12. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(∗). Diabetes Obes Metab. 2011;13:939-946.
13. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258-267.
14. Gallwitz B, Uhlig-Laske B, Battacharaya S, et al. Lina-gliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin. Diabetes. 2011;60:LB11-LB12.
15. Sloan L, Newman J, Sauce C, et al. Safety and efficacy of linagliptin in type 2 diabetes patients with severe renal impairment. Diabetes. 2011;60:A114.
16. Huttner S, Graefe-Mody EU, Withopf B, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008;48:1171-1178.
17. Cooper M, von Eynatten M, Emser A, et al. Efficacy and safety of linagliptin in patients with type 2 diabetes, with and without renal impairment: results from a global phase 3 program. Diabetes. 2011;60(suppl 1):A293.